ID: ALA1078238

Max Phase: Preclinical

Molecular Formula: C14H10ClN3O

Molecular Weight: 271.71

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(Nc1ccccc1Cl)c1n[nH]c2ccccc12

Standard InChI:  InChI=1S/C14H10ClN3O/c15-10-6-2-4-8-12(10)16-14(19)13-9-5-1-3-7-11(9)17-18-13/h1-8H,(H,16,19)(H,17,18)

Standard InChI Key:  OOFRWLRRQQMZSP-UHFFFAOYSA-N

Associated Targets(Human)

Ephrin type-B receptor 3 1881 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 271.71Molecular Weight (Monoisotopic): 271.0512AlogP: 3.47#Rotatable Bonds: 2
Polar Surface Area: 57.78Molecular Species: NEUTRALHBA: 2HBD: 2
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 9.83CX Basic pKa: CX LogP: 3.38CX LogD: 3.38
Aromatic Rings: 3Heavy Atoms: 19QED Weighted: 0.75Np Likeness Score: -2.05

References

1. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD..  (2009)  Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.,  19  (21): [PMID:19783434] [10.1016/j.bmcl.2009.09.010]

Source